ReviewFrontiers in immunology2021
The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Prognostic value of C-reactive protein in patients with melanoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Evaluation of C-reactive protein levels in patients with penile cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Trial
- [Comparison of preoperative nutritional scoring systems for predicting survival in upper tract urothelial carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Evaluating the clinical significance of tumor-expressed C-reactive protein in chromophobe renal cell carcinoma.Scientific reports · 2026Article
- Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis.Cureus · 2025Review
- Article
- COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Modified Glasgow Prognostic Score Incorporating CRP/Albumin Ratio and LDH Levels as Prognostic Indicators in Patients with Multiple Myeloma: A Retrospective Study.Cancer management and research · 2025Article
- Inflammation as a key mediator: linking triglyceride-glucose index to prognosis in non-muscle-invasive bladder cancer.Frontiers in oncology · 2025Article
- Biallelic TYR and TKFC variants in Egyptian patients with OCA1 and new expanded TKFC features.BMC genomics · 2024Article
- Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report.Molecular and clinical oncology · 2024Article
- C-Reactive Protein Pretreatment-Level Evaluation with Histopathological Correlation for Chondrosarcoma Prognosis Assessment-A 15-Year Retrospective Single-Center Study.Diagnostics (Basel, Switzerland) · 2024Article
- Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study.Cancer reports (Hoboken, N.J.) · 2024Review
- Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.Cancer discovery · 2024Article
- Exploration of the causal relationship between inflammatory cytokines and prostate carcinoma: a comprehensive Mendelian randomization study.Frontiers in oncology · 2024Article
- Ionising radiation exposure-induced regulation of selected biomarkers and their impact in cancer and treatment.Frontiers in nuclear medicine · 2024Review
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs.Translational andrology and urology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-Reactive Protein (CRP) is associated with diverse outcomes in patients with, or suspected to have, genitourinary malignancies. CRP levels have been shown to be associated with the probability of a prostate cancer diagnosis in patients with elevated PSA, the probability of biochemical recurrence following definitive treatment for localized prostate cancer, and decreased overall survival for patients with advanced disease. In patients with bladder and kidney cancers, CRP levels have been associated with disease progression, stage, and cancer-specific survival. Despite the abundance of correlative studies, the relationship between CRP levels and genitourinary cancer pathogenesis is not clearly understood. Here, we review the evidence for CRP as a biomarker in genitourinary (GU) cancers, with specific focus on potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.